Collagenase Clostridium histolyticum for the Treatment of Peyronie's Disease: The Development of This Novel Pharmacologic Approach

Published on Jun 1, 2015in The Journal of Sexual Medicine3.649
· DOI :10.1111/jsm.12904
Martin K. Gelbard16
Estimated H-index: 16
Larisa Chagan1
Estimated H-index: 1
James P. Tursi13
Estimated H-index: 13
Abstract Introduction The conception of collagenase Clostridium histolyticum (CCH) as treatment for Peyronie's disease (PD) was a vital first step in providing a nonsurgical, minimally invasive FDA-approved treatment for men with PD. Aim To review the origins, clinical research history, and ultimately FDA approval of collagenase as PD treatment. Methods A PubMed search using (Peyronie's or Peyronie) AND collagenase, and limited to clinical research studies, returned nine papers that were examined in the current review. Results Collagenase as a PD treatment arose in response to a lack of effective nonsurgical treatments and the incomplete understanding of underlying PD etiology. Awareness of dense collagen in PD scarring and parallel initial exploration of collagenase to treat herniated lumbar discs coincided with and inspired laboratory-based investigation of collagenase effects on excised PD plaque tissue. The foundational conceptual work and the critical development of purified injectable collagenase allowed the pursuit of clinical studies. Progression of clinical studies into large-scale robust trials culminated in two important outcomes: development of the first validated, PD-specific measure of psychosexual function, the Peyronie's Disease Questionnaire, and the first FDA-approved treatment for PD. Conclusions Collagenase therapy began as an attempt to modify the structure of PD-related tunica albuginea scarring, despite the lack of a fundamental understanding of the scar's origin. If we wish to advance PD treatment beyond this first effective step, the future needs to bring us full circle to the starting point: We need a greater understanding of the control of collagen deposition and wound healing in men with PD. Gelbard MK, Chagan L, and Tursi JP. Collagenase Clostridium histolyticum for the treatment of Peyronie's disease: The development of this novel pharmacologic approach. J Sex Med 2015;12:1481–1489.
  • References (43)
  • Citations (11)
📖 Papers frequently viewed together
192 Citations
96 Citations
4 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Siddharth G. JainH-Index: 1
#2Ravi MavuduruH-Index: 3
Last. Arup K. MandalH-Index: 21
view all 5 authors...
15 CitationsSource
#1Martin K. Gelbard (UCLA: University of California, Los Angeles)H-Index: 16
#2Irwin Goldstein (UCSD: University of California, San Diego)H-Index: 77
Last. Culley C. Carson (UNC: University of North Carolina at Chapel Hill)H-Index: 46
view all 9 authors...
Purpose: IMPRESS (Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) I and II examined the clinical efficacy and safety of collagenase Clostridium histolyticum intralesional injections in subjects with Peyronie disease. Co-primary outcomes in these identical phase 3 randomized, double-blind, placebo controlled studies included the percent change in the penile curvature abnormality and the change in the Peyronie disease questionnaire symptom bother score from baseline to ...
192 CitationsSource
#1Wayne J.G. Hellstrom (Tulane University)H-Index: 63
#2R. G. FeldmanH-Index: 35
Last. James P. TursiH-Index: 13
view all 6 authors...
Purpose: We validated the Peyronie's Disease Questionnaire (, a 15-question self-reported survey that measures the impact and severity of Peyronie's disease symptoms in 3 domains, including 1) psychological and physical symptoms, 2) penile pain and 3) symptom bother.Materials and Methods: We used baseline data from 2 phase 3 clinical trials (334 and 345 patients, respectively) of collagenase clostridium histolyticum treatment for Peyronie's disease associated penile c...
82 CitationsSource
#2Scott VarneyH-Index: 4
Last. James J. TomasekH-Index: 33
view all 3 authors...
Significance: Myofibroblasts are responsible for wound closure that occurs in healed acute wounds. However, their actions can result in disfiguring scar contractures, compromised organ function, and a tumor promoting stroma. Understanding the mechanisms regulating their contractile machinery, gene expression, and lifespan is essential to develop new therapies to control their function. Recent Advances: Mechanical stress and transforming growth factor beta-1 (TGF-β1) regulate myofibroblast differ...
86 CitationsSource
#1Martin K. GelbardH-Index: 16
#2Larry I. Lipshultz (BCM: Baylor College of Medicine)H-Index: 47
Last. Laurence A. Levine (Rush University)H-Index: 51
view all 6 authors...
Purpose: Collagenase Clostridium histolyticum is an investigational nonsurgical treatment for Peyronie disease. In this phase 2b, double-blind, randomized, placebo controlled study we determined the safety and efficacy of collagenase C. histolyticum and assessed a patient reported outcome questionnaire.Materials and Methods: A total of 147 subjects were randomized into 4 groups to receive collagenase C. histolyticum or placebo (3:1) with or without penile plaque modeling (1:1). Per treatment cyc...
78 CitationsSource
#1Susan Emeigh HartH-Index: 1
Collagen is the primary structural protein of the extracellular matrix. To date, 28 distinct types of collagen have been identified which serve not only as structural components of the interstitial matrix but also function as adhesive and occlusive components of basement membranes, as anchoring fibrils between cells and the interstitium, and as integrative transmembrane proteins. In addition to their structural functions, collagens have a number of physiologically important roles as well. Collag...
4 CitationsSource
#1Andrew G. BreiteH-Index: 10
#2Robert C. McCarthyH-Index: 9
Last. Francis E. DwuletH-Index: 7
view all 3 authors...
Abstract Objectives Clostridium histolyticum expresses two classes of collagenases, C1 and C2. However, degradation of these enzymes by proteases during the fermentation or purification process may lead to numerous molecular forms that lead to inconsistent release of islets from human pancreata. This report defines the amino acid sequence of the truncated forms of C1 (C1b or C1c) that contain a single collagen-binding domain (CBD) and investigates the synergy between the different forms of C1 co...
9 CitationsSource
#1Shaunak S. Desai (Stanford University)H-Index: 4
#2Vincent R. Hentz (Stanford University)H-Index: 34
Importance of the field: Dupuytren's disease is a non-malignant, progressive disorder of the hands that can severely limit hand function and diminish overall quality of life. With global life expectancy increasing, the prevalence of this disease appears to be increasing amongst all ethnic groups. Treatment has traditionally remained surgical with few effective, nonsurgical options. However, with the introduction of collagenase clostridium histolyticum to treat Dupuytren's contractures, physician...
32 CitationsSource
#1David J. RalphH-Index: 46
#2Nestor F. Gonzalez-Cadavid (UCLA: University of California, Los Angeles)H-Index: 59
Last. Laurence A. Levine (Rush Medical College)H-Index: 51
view all 7 authors...
ABSTRACT Introduction The field of Peyronie's disease is evolving and there is need for a state-of-the-art information in this area. Aim To develop an evidence-based state-of-the-art consensus report on the management of Peyronie's disease. Methods To provide state-of-the-art knowledge regarding the prevalence, etiology, medical and surgical management of Peyronie's Disease, representing the opinion of leading experts developed in a consensus process over a 2-year period. Main Outcome Measures E...
242 CitationsSource
#1Nestor F. Gonzalez-Cadavid (UCLA: University of California, Los Angeles)H-Index: 59
#2Jacob Rajfer (UCLA: University of California, Los Angeles)H-Index: 58
Pharmacological treatments for Peyronie's disease generally have limited success. Research using cell culture systems and animal models has provided insights into the fibrotic mechanisms underlying this disease, and has revealed a novel and potentially effective application of phosphodiesterase 5 inhibitors in this context.
56 CitationsSource
Cited By11
#1E. Fernández-Pascual (Hospital Universitario La Paz)
#2L.M. Quintana Franco (Hospital Universitario La Paz)
Last. J.I. Martínez-SalamancaH-Index: 2
view all 5 authors...
Abstract Introduction and objective Surgery is the treatment of choice for patients with Peyronie's disease presenting difficulty in penetration or erectile dysfunction without adequate response to therapy. Several techniques have been described, and urologists must be aware of their possible complications and sequelae in order to offer the patient the best possible alternative. Patients and methods Three complex cases of patients with Peyronie's disease are presented. The first case exposes a c...
#1E. Fernández-Pascual (Hospital Universitario La Paz)
#2L.M. Quintana Franco (Hospital Universitario La Paz)
Last. J.I. Martínez-SalamancaH-Index: 2
view all 5 authors...
Resumen Introduccion y objetivo El tratamiento de eleccion en pacientes con enfermedad de Peyronie con dificultad para la penetracion o disfuncion erectil sin adecuada respuesta a farmacos es la cirugia. Se han descrito multiples tecnicas, y cada una de ellas acarrea posibles complicaciones y secuelas que el urologo debe conocer para ofrecer al paciente la mejor alternativa posible. Pacientes y metodos Se exponen 3 casos complejos de pacientes con enfermedad de Peyronie. El primero de ellos es u...
#1Steven A. Mills (UCLA: University of California, Los Angeles)H-Index: 2
#2Martin K. Gelbard (UCLA: University of California, Los Angeles)H-Index: 16
Purpose The introduction of collagenase Clostridium histolyticum (CCH) as the first and only FDA-approved non-surgical treatment for Peyronie’s disease (PD) has been an important step in its management. Our aim is to provide an overview of the historical origins of CCH and its development through FDA approval and beyond for the treatment of PD.
2 CitationsSource
#1Matthew Ziegelmann (Mayo Clinic)H-Index: 11
#2Landon Trost (Mayo Clinic)H-Index: 23
Last. Laurence A. Levine (Rush University Medical Center)H-Index: 51
view all 3 authors...
While surgery remains the gold standard for the treatment of penile deformity associated with Peyronie’s disease, various non-surgical options including oral and topical agents, penile traction, and intralesional injections are available with varying levels of evidence and treatment efficacy seen in the literature. Herein we review various non-surgical managements for Peyronie’s disease and describe our techniques for intralesional injections with verapamil and Collagenase Clostridium histolytic...
#1R. Avant (Mayo Clinic)H-Index: 3
#2Matthew Ziegelmann (Mayo Clinic)H-Index: 11
Last. Landon Trost (Mayo Clinic)H-Index: 23
view all 6 authors...
Abstract Introduction Peyronie's disease (PD) has historically been managed by at least 1 treatment, including oral supplements or medications, intralesional injections, or surgery. Adjunctive mechanical therapies also have been described, including penile traction therapy (PTT) and vacuum erection devices (VEDs), although relatively limited data are available on their use with PD. Aim To review and summarize the published literature on the role and efficacy of PTT and VED in men with PD. Method...
4 CitationsSource
#1Scott Brimley (Tulane University)H-Index: 1
#2Faysal A. Yafi (UCI: University of California, Irvine)H-Index: 19
Last. Georgios Hatzichristodoulou (University of Würzburg)H-Index: 14
view all 6 authors...
Abstract Introduction Peyronie’s disease (PD) is a fibrotic disorder that leads to plaque formation in ∼3–9% of adult men. Connective tissue buildup results in plaque formation, penile curvature and shortening, and in some cases, pain. In the active phase of PD, penile pain is a common symptom, often accompanied by progression in curvature. Treatment options for PD include oral drugs, topical cream, intralesional injections, traction, and shock wave therapy. This article reviews the different tr...
5 CitationsSource
: Nowadays, enzymatic therapy is a very promising line of treatment for many different diseases. There is a group of disorders and conditions, caused by fibrotic and scar processes and associated with the excessive accumulation of collagen that needs to be catabolized to normalize the connective tissue content. The human body normally synthesizes special extracellular enzymes, matrix metalloproteases (MMPs) by itself. These enzymes can cleave components of extracellular matrix (ECM) and differen...
4 CitationsSource
#1Eric D. Villarreal (UTHSC: University of Tennessee Health Science Center)
#2William Preston Hewgley (UTHSC: University of Tennessee Health Science Center)
Last. John A. Sandoval (Boston Children's Hospital)H-Index: 2
view all 7 authors...
Abstract Background Contained in-bag spleen morcellation is a conventional extraction technique for safe spleen removal during laparoscopic splenectomy. Existing data for the use of in-bag enzymatic splenic digestion as an alternative to morcellation are lacking. This proof-of-concept study sought to evaluate the effectiveness of single and combinatorial enzyme digestion of murine spleens. Materials and methods Murine spleens were digested with collagenase alone or with combinations of commercia...
#1Matthew Ziegelmann (Mayo Clinic)H-Index: 11
#2Boyd R. Viers (Mayo Clinic)H-Index: 15
Last. Landon Trost (Mayo Clinic)H-Index: 23
view all 6 authors...
Objective To evaluate the outcomes in men undergoing collagenase Clostridium histolyticum (CCH) with concurrent penile traction therapy (PTT) for the treatment of Peyronie disease (PD). Materials and Methods We identified patients treated with CCH between March 2014 and July 2016. Patients were recommended to perform modeling and PTT between injection series. A final curve assessment was performed after patients completed CCH. A prospective database was maintained, including patient-reported fre...
16 CitationsSource
#1Pedro ValenteH-Index: 1
#2Carolina Gomes (University of Porto)H-Index: 1
Last. Nuno Tomada (University of Porto)H-Index: 7
view all 3 authors...
Objective To evaluate surgical outcomes and complications and assess overall patient satisfaction after small intestinal submucosa (SIS) grafting for Peyronie disease. Methods Twenty-eight patients were treated with tunical incision and grafting with SIS. Mean age of the patients was 58 (range: 43-71) years. A preoperative protocol was applied to all patients. Patients were also evaluated at follow-up clinic visits. The International Index of Erectile Function, a modified Erectile Dysfunction In...
4 CitationsSource